Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective

References

• BrooksDJSagarHEntacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month studyJ Neurol Neurosurg Psychiatry2003741071912876237
   PubMed Web of Science ®Google Scholar
• ChapuisSImpact of the motor complications of Parkinson’s disease on the quality of lifeMov Disord2005202243015384126
   PubMed Web of Science ®Google Scholar
• ChaudhuriKRNon-motor symptoms of Parkinson’s disease: diagnosis and managementLancet Neurol200652354516488379
   PubMed Web of Science ®Google Scholar
• de la Fuente-FernandezRBiochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnoverAnn Neurol20014929830311261503
   PubMed Web of Science ®Google Scholar
• DorseyERProjected number of people with Parkinson disease in the most populous nations, 2005 through 2030Neurology200768384617082464
   PubMed Web of Science ®Google Scholar
• DupontESustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patientsActa Neurol Scand19969314208825266
   PubMed Web of Science ®Google Scholar
• FahnSDoes levodopa slow or hasten the rate of progression of Parkinson’s disease?J Neurol2005252iv374216222436
   PubMed Web of Science ®Google Scholar
• FungVA randomized, double - blind study to compare the effect on quality of life of levodopa/carbidopa/entacapone (Stalevo) with levodopa/carbidopa in patients with Parkinson’s disease with no or minimal, non-disabling motor fluctuations. Movement Disorder Society of Australia Clinical Research and Trials Group (MDSCRTG) and QUEST-AP Study GroupMov Disord200621S446 Abstract #37
   PubMed Web of Science ®Google Scholar
• GrossetKASuboptimal medication adherence in Parkinson’s diseaseMov Disord2005201502716037924
   PubMed Web of Science ®Google Scholar
• HaapaniemiHTolerability and safety of entacapone in the treatment of Parkinson’s diseaseParkinsonism Relat Disord20017S57
   Web of Science ®Google Scholar
• HollowayRGPramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialArch Neurol20046110445315262734
   PubMed Web of Science ®Google Scholar
• KatzenschlagerRAnticholinergics for symptomatic management of Parkinson’s diseaseCochrane Database Syst Rev2003CD00373512804486
   PubMedGoogle Scholar
• KollerWCImmediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study GroupNeurology1999531012910496260
   PubMed Web of Science ®Google Scholar
• LarsenJPThe tolerability and efficacy of entacapone over 3 years in patients with Parkinson’s diseaseEur J Neurol2003101374612603288
   PubMed Web of Science ®Google Scholar
• LitvanIMovement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disordersMov Disord2003184678612722160
   PubMed Web of Science ®Google Scholar
• Maier HoehnMMParkinsonism treated with levodopa: progression and mortalityJ Neural Transm Suppl198319253646583311
   PubMedGoogle Scholar
• MarsdenCDParkesJDSuccess and problems of long-term levodopa therapy in Parkinson’s diseaseLancet19771345964868
   PubMed Web of Science ®Google Scholar
• MullerTInhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levelsMov Disord200621332616211593
   PubMed Web of Science ®Google Scholar
• MyllylaVTwelve-month safety of entacapone in patients with Parkinson’s diseaseEur J Neurol20018536011509081
   PubMed Web of Science ®Google Scholar
• NissinenHKuoppamakiMLeinonenMEarly initiation of entacapone leads to superior 5-year efficacy compared to delayed initiation in Parkinson’s disease patients receiving traditional levodopa/DDCI therapyMov Disord200621S593
   Google Scholar
• NuttJGFellmanJHPharmacokinetics of levodopaClinical Neuropharmacology1984735496367973
   PubMed Web of Science ®Google Scholar
• NyholmDOptimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tabletsClin Neuropharmacol2003261566312782919
   PubMed Web of Science ®Google Scholar
• OertelWHPergolide versus levodopa monotherapy in early Parkinson’s disease patients: The PELMOPET studyMov Disord2006213435316211594
   PubMed Web of Science ®Google Scholar
• OlanowCWContinuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implicationsLancet Neurol200656778716857573
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupEntacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Parkinson Study GroupAnn Neurol199742747559392574
   PubMed Web of Science ®Google Scholar
• PoeweWHEfficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)Acta Neurol Scand20021052455511939936
   PubMed Web of Science ®Google Scholar
• RascolOA five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study GroupN Engl J Med200034214849110816186
   PubMed Web of Science ®Google Scholar
• RascolODevelopment of dyskinesias in a 5-year trial of ropinirole and L-dopaMov Disord20062118445016958094
   PubMed Web of Science ®Google Scholar
• RinneUKEntacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study GroupNeurology1998511309149818851
   PubMed Web of Science ®Google Scholar
• SawleGVThe effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson’s diseaseNeurology199444129278035933
   PubMed Web of Science ®Google Scholar
• SchapiraAHObesoJTiming of treatment initiation in Parkinson’s disease: a need for reappraisal?Ann Neurol2006595596216489611
   PubMed Web of Science ®Google Scholar
• SilverDEClinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo)Expert Rev Neurother200445899915853578
   PubMedGoogle Scholar
• StalevoUS prescribing information [online]2007 Accessed March 2007. URL: http://www.pharma.us.novartis.com/product/pi/pdf/stalevo.pdf
   Google Scholar
• StocchiFOptimising levodopa therapy for the management of Parkinson’s diseaseJ Neurol2005252IV43816222437
   PubMed Web of Science ®Google Scholar
• StocchiFThe levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerationsExpert Opin Pharmacother20067139940716805724
   PubMedGoogle Scholar
• WheatleyKEvaluating drug treatments for Parkinson’s disease: how good are the trials?BMJ200232415081112077043
   PubMed Web of Science ®Google Scholar